Araştırma Makalesi
PDF Zotero Mendeley EndNote BibTex Kaynak Göster

Vücut Kitle İndeksi değerlerine göre ayarlanabilir intragastrik balon kullanım sonuçları

Yıl 2022, Cilt 12, Sayı 2, 339 - 343, 15.03.2022
https://doi.org/10.16899/jcm.1058508

Öz

Amaç: Çalışmamızda hastalarda ayarlanabilir intragastrik balonların sonuçlarının vücut kitle indeksine göre karşılaştırılması amaçlandı. Gereç ve Yöntem: Son dört yılda AIGB işlemi yaptığımız 82 hastanın verilerini kaydettik. Balonun ilk implantasyonu sırasında 300-350 cc salin ve metilen mavisi ile şişirme yapıldı. Hastaların ve balonun çıkarıldığı anki vücut kitle indeks değerleri(VKİ) ve kilo verme oranları(EWL) not edildi. Hastaların balon uygulaması veya ek şişirme sonrası oluşan şikayetleri ve komplikasyonları kaydedildi. Bulgular: VKİ ve EWL değerleri arasında ilk uygulama yapıldıktan sonra 4., 8. ve 12. aylarda ölçülen kilolarla istatistiksel olarak anlamlı azalma olduğu belirlendi., (p<0,001). Ağırlık ve EWL değerleri morbid obez (VKİ ≥40) ve VKİ <40 olan hastalar olmak üzere iki grupta değerlendirildi. Her iki grupta da zamana bağlı olarak ağırlık ve EWL değerlerinde istatistiksel olarak anlamlı azalma olduğu belirlendi (p<0,001). İleri analizde, morbid obez hastalarda (BMI≥40) EWL değerleri için 8. ve 12. aylar arasındaki fark istatistiksel olarak anlamlı değildi (p>0.05), diğer tüm farklılıklar istatistiksel olarak anlamlıydı (p<0.001). Sonuç: AIGB tedavisi morbid obez hastalarda tatmin edici sonuçlara sahiptir. Morbid obez hastalarda. AIGB, cerrahinin ek hastalıklar nedeniyle risk taşıyabileceği veya hastaların cerrahiyi tercih etmediği durumlarda kilo vermek için kullanılabilecek cerrahi olmayan alternatif bir yöntem olarak tercih edilebilir.

Kaynakça

  • Buchwald H, Avidor Y, et al. Buchwald, H., Avidor, Y., Braunwald, E., Jensen, M. D., Pories, W., Fahrbach, K. JAMA 2004; 292: 1724-37.
  • Salcan S. , Ezmeci T. Obesity Prevalence and Effective Factors in High School Students in Erzincan City Center. J Contemp Med. 2021; 11(3): 330-334.
  • Mathus-Vliegen EM. Intragastric balloon treatment for obesity: what does it really offer? Dig Dis. 2008;26(1):40–4.
  • Brooks J, Srivastava ED, Mathus-Vliegen, E. M. H. One-year adjustable intragastric balloons: results in 73 consecutive patients in the U.K. Obes Surg. 2014 May;24(5):813-9. doi: 10.1007/s11695-014-1176-3.
  • Bustamante, F., Brunaldi, V. O., Bernardo, W. M., de Moura, D. T. H., de Moura, E. T. H., Galvão, M. et al. Obesity Treatment with Botulinum Toxin-A Is Not Effective: a Systematic Review and Meta-Analysis. Obesity Surgery, October 2017, Volume 27, Issue 10, pp 2716–2723.
  • Machytka, E., Klvana, P., Kornbluth, A., Peikin, S., Mathus-Vliegen, L. E., Gostout, C. et al. Adjustable intragastric balloons: a 12-month pilot trial in endoscopic weight loss management. Obes Surg 2011; 21: 1499-1507.
  • Mathus-Vliegen EM. Endoscopic treatment: the past, the present and the future. Best Pract Res Clin Gastroenterol 2014; 28: 685-702.
  • Yanovski S.Z., Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA 2014; 311: 74-86.
  • Chang, S. H., Stoll, C. R., Song, J., Varela, J. E., Eagon, C. J., & Colditz, G. A. , et al. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003-2012. JAMA Surg 2014; 149: 275-287.
  • Usuy E, Brooks J. Response Rates with the Spatz3 Adjustable Balloon. Obes Surg. 2018 May;28(5):1271-1276.
  • Calle, E. E., Thun, M. J., Petrelli, J. M., Rodriguez, C., & Heath Jr, C. W. Bodymass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999; 341: 1097-1105.
  • Mitura K, Garnysz K. In search of the ideal patient for the intragastric balloon - short- and long-term results in 70 obese patients. Wideochir Inne Tech Maloinwazyjne 2016; 10: 541-547.
  • Mion, F., Ibrahim, M., Marjoux, S., Ponchon, T., Dugardeyn, S., Roman, S. et al. Swallowable Obalon® gastric balloons as an aid for weight loss: a pilot feasibility study. Obes Surg 2013; 23: 730-733.
  • Kim SH, Chun HJ, et al. Current status of intragastric balloon for obesity treatment. World J Gastroenterol. 2016; 5495-504.
  • Bayraktar O. , Özçelik A. A. , Öktemgil A. R. , Bayraktar B. Intragastric balloon therapy for obesity: Is it safe and effective?. ACEM. 2019; 4(1): 25-28.
  • Gaur S, Levy S, et al. Balancing risk and reward: a critical review of the intragastric balloon for weight loss. Gastrointest Endosc 2015; 81: 1330-1336.

Results of adjustable intragastric balloon use according to Body Mass Index values

Yıl 2022, Cilt 12, Sayı 2, 339 - 343, 15.03.2022
https://doi.org/10.16899/jcm.1058508

Öz

Aim: In our study, it was aimed to compare the results of adjustable intragastric balloons in patients according to body mass index. Material and Method: We recorded the data of 82 patients that we performed AIGB procedure in the last four years. During the initial implantation of the balloon, inflating was performed with 300-350 cc saline and methylene blue. Body mass index values and excess weight loss ratios of the patients at the time of the balloon removal were noted. Patients' complaints and complications arising after balloon application or additional inflation were reported. Results: It was determined that there was a statistically significant decrease between weight, BMI, and EWL values measured at the 4th, 8th, and 12th months after the first application was performed (p <0.001). The weight and EWL values were evaluated in two groups as morbidly obese (BMI ≥40) and patients with BMI <40.İt was determined that there was a statistically significant decrease in weight and EWL values in both groups depending on time (p <0.001), in further analysis, the difference between the 8th and 12th months for EWL values was not statistically significant (p>0.05) in morbidly obese patients (BMI≥40), all other differences were statistically significant (p<0.001). Conclusion: AIGB treatment has satisfactory results in morbidly obese patients. In morbidly obese patients. AIGB may be preferred as an alternative non-surgical method that can be used for weight loss in cases where surgery may carry risk due to co-morbidities or when patients do not prefer surgery.

Kaynakça

  • Buchwald H, Avidor Y, et al. Buchwald, H., Avidor, Y., Braunwald, E., Jensen, M. D., Pories, W., Fahrbach, K. JAMA 2004; 292: 1724-37.
  • Salcan S. , Ezmeci T. Obesity Prevalence and Effective Factors in High School Students in Erzincan City Center. J Contemp Med. 2021; 11(3): 330-334.
  • Mathus-Vliegen EM. Intragastric balloon treatment for obesity: what does it really offer? Dig Dis. 2008;26(1):40–4.
  • Brooks J, Srivastava ED, Mathus-Vliegen, E. M. H. One-year adjustable intragastric balloons: results in 73 consecutive patients in the U.K. Obes Surg. 2014 May;24(5):813-9. doi: 10.1007/s11695-014-1176-3.
  • Bustamante, F., Brunaldi, V. O., Bernardo, W. M., de Moura, D. T. H., de Moura, E. T. H., Galvão, M. et al. Obesity Treatment with Botulinum Toxin-A Is Not Effective: a Systematic Review and Meta-Analysis. Obesity Surgery, October 2017, Volume 27, Issue 10, pp 2716–2723.
  • Machytka, E., Klvana, P., Kornbluth, A., Peikin, S., Mathus-Vliegen, L. E., Gostout, C. et al. Adjustable intragastric balloons: a 12-month pilot trial in endoscopic weight loss management. Obes Surg 2011; 21: 1499-1507.
  • Mathus-Vliegen EM. Endoscopic treatment: the past, the present and the future. Best Pract Res Clin Gastroenterol 2014; 28: 685-702.
  • Yanovski S.Z., Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA 2014; 311: 74-86.
  • Chang, S. H., Stoll, C. R., Song, J., Varela, J. E., Eagon, C. J., & Colditz, G. A. , et al. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003-2012. JAMA Surg 2014; 149: 275-287.
  • Usuy E, Brooks J. Response Rates with the Spatz3 Adjustable Balloon. Obes Surg. 2018 May;28(5):1271-1276.
  • Calle, E. E., Thun, M. J., Petrelli, J. M., Rodriguez, C., & Heath Jr, C. W. Bodymass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999; 341: 1097-1105.
  • Mitura K, Garnysz K. In search of the ideal patient for the intragastric balloon - short- and long-term results in 70 obese patients. Wideochir Inne Tech Maloinwazyjne 2016; 10: 541-547.
  • Mion, F., Ibrahim, M., Marjoux, S., Ponchon, T., Dugardeyn, S., Roman, S. et al. Swallowable Obalon® gastric balloons as an aid for weight loss: a pilot feasibility study. Obes Surg 2013; 23: 730-733.
  • Kim SH, Chun HJ, et al. Current status of intragastric balloon for obesity treatment. World J Gastroenterol. 2016; 5495-504.
  • Bayraktar O. , Özçelik A. A. , Öktemgil A. R. , Bayraktar B. Intragastric balloon therapy for obesity: Is it safe and effective?. ACEM. 2019; 4(1): 25-28.
  • Gaur S, Levy S, et al. Balancing risk and reward: a critical review of the intragastric balloon for weight loss. Gastrointest Endosc 2015; 81: 1330-1336.

Ayrıntılar

Birincil Dil İngilizce
Konular Sağlık Bilimleri ve Hizmetleri
Bölüm Orjinal Araştırma
Yazarlar

Veysel Barış TURHAN (Sorumlu Yazar)
University of Hitit, Erol Olçok Training and Research Hospital, Department of General Surgery, Çorum, TURKEY
0000-0001-5093-4993
Türkiye


Doğan ÖZTÜRK
University of Medical Sciences, Kecioren Training and Research Hospital, Department of General Surgery, Ankara, TURKEY
0000-0003-1754-9246
Türkiye


Mutlu ŞAHİN
Ankara Koru Hospital, Department of General Surgery,Ankara, TURKEY
0000-0003-0371-4095
Türkiye


Müge KESKİN
Ankara Numune Training and Research Hospital, Deparment of Endocrinology, Ankara, 06100, TURKEY
0000-0003-2334-137X
Türkiye


Hakan BULUŞ
University of Medical Sciences, Kecioren Training and Research Hospital, Department of General Surgery, Ankara, TURKEY
0000-0003-2555-4707
Türkiye

Erken Görünüm Tarihi 1 Ocak 2022
Yayımlanma Tarihi 15 Mart 2022
Kabul Tarihi 16 Şubat 2022
Yayınlandığı Sayı Yıl 2022, Cilt 12, Sayı 2

Kaynak Göster

AMA Turhan V. B. , Öztürk D. , Şahin M. , Keskin M. , Buluş H. Results of adjustable intragastric balloon use according to Body Mass Index values. J Contemp Med. 2022; 12(2): 339-343.